SCHEMBL8301615

SCHEMBL8301615

O=C1Nc2ccc(C(=O)O)cc2C1=Cc1ccnc2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 9/20 0.58
JAK3 P52333 2/20 0.55
PDPK1 O15530 1/20 0.55
FCER2 P06734 1/20 0.48
SYK P43405 1/20 0.48
PIM1 P11309 1/20 0.48
CDK2 P24941 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDR P35968 4/20 0.47
PDGFRB P09619 3/20 0.47
FGFR1 P11362 3/20 0.47
SRC P12931 1/20 0.47
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
RAF1 P04049 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8530207 0.88 TLK2 (0.53) TLK2JAK3
SCHEMBL8292593 0.88 PDPK1 (0.58) TLK2PDPK1FCER2SYKMEN1
SCHEMBL8526923 0.86 GSK3B (0.51) TLK2MEN1KMT2AGAAMAPK1
SCHEMBL8529758 0.85 PDPK1 (0.52) PDPK1MEN1KMT2AKDRPDGFRB
SCHEMBL1389040 0.84 TLK2 (0.55) TLK2JAK3PDPK1FCER2SYK
SCHEMBL7131127 0.83 NTRK1 (0.47) SYKPIM1MEN1KMT2AKDR
SCHEMBL8508649 0.83 RPS6KA3 (0.54) PDPK1FCER2SYKMEN1KMT2A
SCHEMBL8530158 0.83 RET (0.45) PDPK1SYKMEN1KMT2A
SCHEMBL5728227 0.82 CHEK1 (0.60) TLK2MEN1KMT2AKDRPDGFRB
SCHEMBL5728224 0.82 CHEK1 (0.60) TLK2MEN1KMT2AKDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0752985-B1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA & UPJOHN SPA (IT) 1999-08-04 EP disclosed
US-5840745-A INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY PHARMACIA S. P. A. (IT) 1998-11-24 US disclosed